These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 35352313)

  • 1. Collagen Turnover Biomarkers Associate with Active Psoriatic Arthritis and Decrease with Guselkumab Treatment in a Phase 3 Clinical Trial (DISCOVER-2).
    Schett G; Loza MJ; Palanichamy A; FitzGerald O; Ritchlin C; Bay-Jensen AC; Nielsen SH; Gao S; Hsia EC; Kollmeier AP; Xu XL; Baribaud F; Sweet K
    Rheumatol Ther; 2022 Aug; 9(4):1017-1030. PubMed ID: 35352313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Guselkumab demonstrated an independent treatment effect in reducing fatigue after adjustment for clinical response-results from two phase 3 clinical trials of 1120 patients with active psoriatic arthritis.
    Rahman P; Mease PJ; Helliwell PS; Deodhar A; Gossec L; Kavanaugh A; Kollmeier AP; Hsia EC; Zhou B; Lin X; Shawi M; Karyekar CS; Han C
    Arthritis Res Ther; 2021 Jul; 23(1):190. PubMed ID: 34261541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differentiating patients with psoriasis from psoriatic arthritis using collagen biomarkers.
    Holm Nielsen S; Magee C; Groen SS; Sinkevičiūtė D; Bay-Jensen AC; Karsdal MA; Pennington SR; FitzGerald O
    Clin Exp Rheumatol; 2023 Mar; 41(3):574-580. PubMed ID: 35916294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of guselkumab on serum biomarkers in patients with active psoriatic arthritis and inadequate response to tumor necrosis factor inhibitors: results from the COSMOS phase 3b study.
    Schett G; Chen W; Gao S; Chakravarty SD; Shawi M; Lavie F; Zimmermann M; Sharaf M; Coates LC; Siebert S
    Arthritis Res Ther; 2023 Aug; 25(1):150. PubMed ID: 37587493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extracellular matrix turnover biomarkers reflect pharmacodynamic effects and treatment response of adalimumab in patients with axial spondyloarthritis-results from two randomized controlled trials.
    Port H; Holm Nielsen S; Frederiksen P; Madsen SF; Bay-Jensen AC; Sørensen IJ; Jensen B; Loft AG; Madsen OR; Østergaard M; Pedersen SJ
    Arthritis Res Ther; 2023 Aug; 25(1):157. PubMed ID: 37626399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of n-3 PUFA on extracellular matrix protein turnover in patients with psoriatic arthritis: a randomized, double-blind, placebo-controlled trial.
    Holm Nielsen S; Sardar S; Siebuhr AS; Schlemmer A; Schmidt EB; Bay-Jensen AC; Karsdal MA; Christensen JH; Kristensen S
    Rheumatol Int; 2021 Jun; 41(6):1065-1077. PubMed ID: 33885930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of Interleukin-23 Signaling With Guselkumab in Biologic-Naive Patients Versus Tumor Necrosis Factor Inhibitor-Inadequate Responders With Active Psoriatic Arthritis.
    Siebert S; Coates LC; Schett G; Raychaudhuri SP; Chen W; Gao S; Seridi L; Chakravarty SD; Shawi M; Lavie F; Sharaf M; Zimmermann M; Kollmeier AP; Xu XL; Rahman P; Mease PJ; Deodhar A
    Arthritis Rheumatol; 2024 Jun; 76(6):894-904. PubMed ID: 38253404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extracellular matrix protein turnover markers are associated with axial spondyloarthritis-a comparison with postpartum women and other non-axial spondyloarthritis controls with or without back pain.
    Port H; Nielsen SH; Madsen SF; Bay-Jensen AC; Karsdal M; Seven S; Sørensen IJ; Morsel-Carlsen L; Østergaard M; Pedersen SJ
    Arthritis Res Ther; 2022 Jun; 24(1):152. PubMed ID: 35739562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Longitudinal change in collagen degradation biomarkers in idiopathic pulmonary fibrosis: an analysis from the prospective, multicentre PROFILE study.
    Jenkins RG; Simpson JK; Saini G; Bentley JH; Russell AM; Braybrooke R; Molyneaux PL; McKeever TM; Wells AU; Flynn A; Hubbard RB; Leeming DJ; Marshall RP; Karsdal MA; Lukey PT; Maher TM
    Lancet Respir Med; 2015 Jun; 3(6):462-72. PubMed ID: 25770676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of guselkumab on inhibiting radiographic progression in patients with active psoriatic arthritis: study protocol for APEX, a Phase 3b, multicenter, randomized, double-blind, placebo-controlled trial.
    Ritchlin CT; Coates LC; Mease PJ; van der Heijde D; Song J; Jiang Y; Shawi M; Kollmeier AP; Rahman P
    Trials; 2023 Jan; 24(1):22. PubMed ID: 36627711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studies.
    Ritchlin CT; Mease PJ; Boehncke WH; Tesser J; Schiopu E; Chakravarty SD; Kollmeier AP; Xu XL; Shawi M; Jiang Y; Sheng S; Wang Y; Xu S; Merola JF; McInnes IB; Deodhar A
    RMD Open; 2022 Mar; 8(1):. PubMed ID: 35296534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigating protease-mediated peptides of inflammation and tissue remodeling as biomarkers associated with flares in psoriatic arthritis.
    Groen SS; Nielsen SH; Bay-Jensen AC; Rasti M; Ganatra D; Oikonomopoulou K; Chandran V
    Arthritis Res Ther; 2024 May; 26(1):107. PubMed ID: 38802975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum biomarkers of collagen turnover as potential diagnostic tools in diffuse systemic sclerosis: A cross-sectional study.
    Juhl P; Bay-Jensen AC; Karsdal M; Siebuhr AS; Franchimont N; Chavez J
    PLoS One; 2018; 13(12):e0207324. PubMed ID: 30507931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Effect of Guselkumab on Work Productivity in Biologic-Naïve Patients with Active Psoriatic Arthritis Through Week 52 of the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Trial.
    Curtis JR; McInnes IB; Rahman P; Gladman DD; Peterson S; Agarwal P; Yang F; Kollmeier AP; Hsia EC; Shiff NJ; Zhou B; Han C; Shawi M; Tillett W; Mease PJ
    Adv Ther; 2022 Oct; 39(10):4613-4631. PubMed ID: 35947349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial.
    Mease PJ; Rahman P; Gottlieb AB; Kollmeier AP; Hsia EC; Xu XL; Sheng S; Agarwal P; Zhou B; Zhuang Y; van der Heijde D; McInnes IB;
    Lancet; 2020 Apr; 395(10230):1126-1136. PubMed ID: 32178766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-Term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin-23, Through Two Years: Results From a Phase III, Randomized, Double-Blind, Placebo-Controlled Study Conducted in Biologic-Naive Patients With Active Psoriatic Arthritis.
    McInnes IB; Rahman P; Gottlieb AB; Hsia EC; Kollmeier AP; Xu XL; Jiang Y; Sheng S; Shawi M; Chakravarty SD; van der Heijde D; Mease PJ
    Arthritis Rheumatol; 2022 Mar; 74(3):475-485. PubMed ID: 34719872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dysregulation of circulating collagen turnover markers in very early systemic sclerosis.
    Dobrota R; Jordan S; Juhl P; Del Papa N; Maurer B; Becker M; Mihai C; Bay-Jensen AC; Karsdal MA; Siebuhr AS; Distler O
    RMD Open; 2024 May; 10(2):. PubMed ID: 38806188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of patient endotypes and adalimumab treatment responders in axial spondyloarthritis using blood-derived extracellular matrix biomarkers.
    Port H; Christiansen F; Nielsen SH; Frederiksen P; Bay-Jensen AC; Karsdal MA; Seven S; Sørensen IJ; Loft AG; Madsen OR; Ostergaard M; Pedersen SJ
    RMD Open; 2024 Jan; 10(1):. PubMed ID: 38199849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Levels of extracellular matrix metabolites are associated with changes in Ankylosing Spondylitis Disease Activity Score and MRI inflammation scores in patients with axial spondyloarthritis during TNF inhibitor therapy.
    Holm Nielsen S; Sun S; Bay-Jensen AC; Karsdal M; Sørensen IJ; Weber U; Loft AG; Kollerup G; Thamsborg G; Madsen OR; Møller J; Østergaard M; Pedersen SJ
    Arthritis Res Ther; 2022 Dec; 24(1):279. PubMed ID: 36564778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Guselkumab, an Interleukin-23p19-Specific Monoclonal Antibody, Through One Year in Biologic-Naive Patients With Psoriatic Arthritis.
    McInnes IB; Rahman P; Gottlieb AB; Hsia EC; Kollmeier AP; Chakravarty SD; Xu XL; Subramanian RA; Agarwal P; Sheng S; Jiang Y; Zhou B; Zhuang Y; van der Heijde D; Mease PJ
    Arthritis Rheumatol; 2021 Apr; 73(4):604-616. PubMed ID: 33043600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.